Validity and responsiveness of the self-administered computerized versions of the baseline and transition dyspnea indexes

Chest

Volumn 132, Issue 4, 2007, Pages 1283-1290

  Mahler, Donald A ^a   Waterman, Laurie A ^a   Ward, Joseph ^a   McCusker, Corliss ^b   ZuWallack, Richard ^b   Baird, John C ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

COPD; Lung function; Medical Research Council scale; Patient reported breathlessness

Indexed keywords

ADULT; AGED; ARTICLE; BASELINE DYSPNEA INDEX; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER SYSTEM; CORRELATION ANALYSIS; CORRELATION FUNCTION; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DYSPNEA; EVALUATION; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; INSPIRATORY CAPACITY; INTERVIEW; LONGITUDINAL STUDY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; TRANSITION DYSPNEA INDEX; VALIDATION PROCESS;

EID: 35448989756     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.07-0703     Document Type: Article

References (47)

1. Bausewein C, Farquhar M, Booth S, et al. Measurement of breathlessness in advanced disease: a systematic review. Respir Med 2007; 101:399-410
2. Mahler DA. Measurement of dyspnea: clinical ratings. In: Mahler DA, O'Donnell DE, eds. Dyspnea: mechanisms, measurement, and management. Boca Raton, FL: Taylor & Francis, 2005; 147-165
3. Fletcher CM, Elmes PC, Fairbairn AS, et al. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. BMJ 1959; 2:257-266
4. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:1005-1012
5. Nishimura K, Izumi T, Tsukino M, et al. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121:1434-1440
6. Hernandez MT, Rubio TM, Ruiz FO, et al. Results of a home-based training program for patients with COPD. Chest 2000; 118:106-114
7. 2-agonist. Pulm Pharmacol Ther 2006 [Epub ahead of print]
8. de Torres JP, Pinto-Plata V, Ingenito E, et al. Power of outcome measurements to detect clinically significant changes in pulmonary rehabilitation of patients with COPD. Chest 2002; 121:1092-1098
9. Kardos P, Wencker M, Glaab T, et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:144-149
10. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85:751-758
11. Harver A, Mahler DA, Daubenspeck JA. Targeted inspiratory muscle training improves respiratory muscle function and reduces dyspnea in patients with chronic obstructive pulmonary disease. Ann Intem Med 1989; 111:117-124
12. Lisboa C, Munoz V, Beroiza T, et al. Inspiratory muscle training in chronic airflow limitation: comparison of two different training loads with a threshold device. Eur Respir J 1994; 7:1266-1274
13. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19:217-224
14. Martinez FJ, de Oca MM, Whyte RI, et al. Lung-volume reduction improves dyspnea, dynamic hyperinflation, and respiratory muscle function. Am J Respir Crit Care Med 1997; 155:1984-1990
15. Reardon J, Awad E, Normandin E, et al. The effect of comprehensive outpatient pulmonary rehabilitation on dyspnea. Chest 1994; 105:1046-1052
16. Ries AL, Kaplan RM, Myers R, et al. Maintenance after pulmonary rehabilitation in chronic lung disease: a randomized trial. Am J Respir Crit Care Med 2003; 167:880-888
17. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58:399-404
18. Kirsten DK, Wegner RE, Jorres RA, et al. Effects of theophylline withdrawal in severe chronic obstructive pulmonary disease. Chest 1993; 104:1101-1107
19. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115:957-965
20. Mahler DA, Huang S, Tabrizi M, et al. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 2004; 126:926-934
21. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23:832-840
22. 2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163:1087-1092
23. Weiner P, Magadle R, Beckerman M, et al. Maintenance of inspiratory muscle training in COPD patients: one year follow-up. Eur Respir J 2004; 23:61-65
24. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124:834-843
25. Mahler DA, Ward J, Fierro-Carrion G, et al. Development of self-administered versions of the modified baseline and transition dyspnea indexes in COPD. COPD 2004; 1:165-172
26. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932-946
27. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 1988; 93:580-586
28. Schunemann HJ, Goldstein R, Mador MJ, et al. A randomised trial to evaluate the self-administered standardised chronic respiratory questionnaire. Eur Respir J 2005; 25:31-40
29. Mahler DA, Harver A. A factor analysis of dyspnea ratings, respiratory muscle strength, and lung function in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 145:467-470
30. Ries AL, Kaplan RM, Blumberg E. Use of factor analysis to consolidate multiple outcome measures in chronic obstructive pulmonary disease. J Clin Epidemiol 1991; 44:497-503
31. Hajiro T, Nishimura K, Tsukino M, et al. Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158:1185-1189
32. ZuWallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001; 119:1661-1670
33. Goldstein RS, Gort EH, Stubbing D, et al. Randomised controlled trial of respiratory rehabilitation. Lancet 1994; 344:1394-1397
34. Jones PW, Agusti AG. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 2006; 27:822-832
35. Barnes PJ, Chowdhury B, Kharitonov SA, et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174:6-14
36. Witek TJ Jr, Mahler DA. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003; 56:248-255
37. Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003; 21:267-272
38. Pitta F, Troosters T, Spruit MA, et al. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171:972-977
39. Osoba D. Interpreting the meaningfulness of changes in health-related quality of life scores: lessons from studies in adults. Int J Cancer Suppl 1999; 12:132-137
40. Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16:139-144
41. Liang MH. Longitudinal construct validity: establishment of clinical meaning in patient evaluative instruments. Med Care 2000; 38:II84-II90
42. Barck AL. Measurement of clinical change caused by knee replacement: conventional score or special change indexes? Arch Orthop Trauma Surg 1999; 119:76-78
43. Bennett KJ, Torrance GW, Moran LA, et al. Health state utilities in knee replacement surgery: the development and evaluation of McKnee. J Rheumatol 1997; 24:1796-1805
44. Mangione CM, Goldman L, Orav EJ, et al. Health-related quality of life after elective surgery: measurement of longitudinal changes. J Gen Intern Med 1997; 12:686-697
45. Fischer D, Stewart AL, Bloch DA, et al. Capturing the patient's view of change as a clinical outcome measure. JAMA 1999; 282:1157-1162
46. Norman GR. The relation between the minimally important difference and patient benefit. COPD 2005; 2:69-73
47. Guyatt GH, Norman GR, Juniper EF, et al. A critical look at transition ratings. J Clin Epidemiol 2002; 55:900-908